Over 300 million people worldwide are affected by 10,867 rare diseases¹, and the overwhelming majority of these conditions lack approved treatments. Addressing this gap requires more than scientific innovation; it demands a systematic, patient-centered approach across the entire drug development process.  

However, the development of rare disease drugs comes with inherent complexities: small and dispersed patient populations, limited clinical knowledge, and a lack of established endpoints. These challenges demand a deeper understanding of the patient experience to develop relevant, feasible, and impactful therapies.  

Systematic patient engagement and patient experience data collection, integrated early and sustained across all phases of drug development, is the most effective way to address these complexities. When patients with rare diseases are involved as partners from the outset, their insights guide decision-making, reduce development risks, and enhance the overall value proposition of the treatment.  

This article explores what a systematic patient engagement strategy in rare disease looks like and how it delivers value across clinical, regulatory, market access, and beyond.  

Moving Beyond Tactics: Embracing Systematic Engagement in Rare Disease  

True systematic patient engagement spans every phase of the process, from early research and development through clinical trials, regulatory submissions, market access, launch, and long-term post-market support. The following examples highlight key patient engagement activities at different stages of development. However, they are not exhaustive, as each rare disease and treatment pathway requires a customized patient engagement approach, shaped by the specific needs of its patient community.  

Patient Input in Clinical Trial Design  

Patients and patient advocacy groups play a critical role in shaping clinical development. They help identify key unmet needs and relevant outcomes, guiding the entire strategy from the beginning. For example, patient reported outcomes may be used to capture symptoms like serious fatigue that are difficult to quantify but essential to understanding quality of life.   

Additionally, patients with rare diseases provide invaluable insights into trial feasibility, advising whether schedules, locations, and procedures are realistic for people living with their conditions. Engaging patient advocacy groups can also enhance patient recruitment, a frequent challenge in rare disease trials.  

Patient Involvement in Regulatory Processes 

Regulators such as the Food and Drug Administration and the European Medicines Agency increasingly involve patients during approval discussions to better understand unmet needs and treatment expectations. Companies should respond by engaging patients early to capture their perspectives, thereby strengthening regulatory submissions and facilitating approval.  

Patient engagement early in development helps identify and capture endpoints that reflect quality-of-life improvements, complement statistical outcomes with lived-experience narratives, and provide context that clarifies disease burden and treatment value, especially important in rare diseases. By linking clinical outcomes with patient-defined benefits, companies build stronger, more credible submissions and patient-informed value stories that resonate with decision-makers.  

Patient Insights in Market Access Strategies  

Patient engagement is equally vital in market access, which is often hindered in rare diseases by incomplete or underpowered data sets. Systematic patient engagement helps companies understand what types of evidence matter most to patients and will resonate with payers.  

Patient value stories help payers grasp the real-world impact of treatments, which is often missed by traditional clinical data. Through qualitative market research, companies can explore the emotional and practical burdens of the disease and translate these findings into compelling value dossiers. Payers, especially in rare diseases, welcome this patient-informed evidence as it contextualizes clinical outcomes and addresses evidence gaps.  

Patient Input for Post-Launch Patient Support and Real-World Evidence Generation

After launch, continued patient engagement supports treatment adherence and long-term outcomes. Rare disease patients often face complex social, economic, and psychological challenges alongside their clinical condition. Through systematic engagement, companies ensure that treatment plans and support programs are tailored to patient lifestyles, communication materials reflect a shared language with patients, and barriers to adherence, such as complexity, burden, or misunderstanding, are proactively addressed.  

Patient registries designed with patient input can also facilitate the collection of real-world evidence to demonstrate ongoing treatment value.  

Conclusion  

The foundation of successful rare disease drug development is early, consistent, and cross-functional patient engagement. This is not the responsibility of a single department; the entire organization should embed this systematic approach in everything they do.   

Patient engagement is not just about collecting patient experience data, although that is key. It’s about building long-term relationships with people whose lives depend on these treatments. It’s about designing strategies around their realities, meeting their expectations, and ultimately improving their outcomes.  

In rare disease development, there is no stronger lever for innovation, differentiation, and access than systematically putting patients at the center of the process from beginning to end. 

How Alira Health Can Help 

Rare diseases present unparalleled challenges for patients. At Alira Health, we help companies develop and commercialize rare disease treatments with the intense focus on the unique needs of rare disease patients that is crucial to your success. With a continuum of patient-centric solutions, we work with you to successfully develop and provide life-changing treatments to the patients. 

From clinical trial patient recruitment and retention to crafting a patient-centric product strategy, our transversal team stands by you every step of the way. 

Sources

1. Rare Diseases International. https://www.rarediseasesinternational.org/living-with-a-rare-disease/.